ZKY 017
Alternative Names: ZKY-017Latest Information Update: 21 Dec 2020
Price :
$50 *
At a glance
- Originator China Ophthalmology Focus
- Developer Lee's Pharmaceutical; Zhaoke Ophthalmology Limited
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 10 Dec 2020 Preclinical trials in Eye disorders in China (unspecified route), prior to December 2020 (Lee's Pharmaceutical pipeline, December 2020)